The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training. Projects are selected through open calls for proposals.
The research consortia participating in IMI projects consist of:

• large biopharmaceutical companies that are members of EFPIA,
• and a variety of other partners, such as:
• small- and medium-sized enterprises,
• patients' organisations,
• universities and other research organisations,
• hospitals,
• regulatory agencies,
• any other industrial partners.